Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Lower Limb

Trial Profile

Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Lower Limb

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Acronyms PLUS
  • Sponsors Merz Pharmaceuticals GmbH
  • Most Recent Events

    • 07 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Jun 2014 Planned End Date changed from 1 Aug 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
    • 30 Jun 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top